From: Improving the use of research evidence in guideline development: 16. Evaluation
Yes | Questions | Reference Points | |
---|---|---|---|
Origin | |||
1 | Are the Cluster and Department issuing the guidelines clearly identified? | Introduction | |
Objective, target audience | |||
2 | Does the guideline list its objectives, including the patient categories and situation(s) for which the guidelines are intended? | Introduction | |
3 | Does the guideline describe the professional groups to which it is addressed? | Introduction | |
Guideline Development Group | |||
4 | Does the Guideline Development Group include all relevant professional groups, public health experts and end users, including individuals from geographic areas where the guidelines will be applied? | List of members of the guideline development group | |
5 | Does the Group include methodological experts in fields such as search methodology, critical appraisal and cost-effectiveness analysis? | List of members of the guideline development group | |
Conflict of interest | |||
6 | Are all funding sources named, and is there no conflict of interest? | List of funding sources | |
7 | Have all members of the Guideline Development Group and external reviewers declared their interests, and have these interests been recorded in the guideline document? | Annex on documentation of process | |
8 | Does the document describe the method used to minimize any undue influence on the Guideline Development Group and the external reviewers? | Annex on documentation of process | |
Evidence | |||
9 | Was there a systematic comprehensive search for evidence, and has the search strategy been recorded in the guideline? | Annex on documentation of process | |
10 | Has the strength and quality of the evidence on effectiveness been graded? | Annex on documentation of process; evidence table | |
11a | What percent of recommendations are evidence-based?* | Summary of recommendations | |
11b | Are the recommendations which are not evidence-based explicitly labeled as "expert opinion" based? | Summary of recommendations | |
12 | Is there explicit consideration of other issues, such as safety and potential misuse in a variety of settings? | Annex on documentation of process; evidence table | |
13 | Is there explicit consideration of issues of cost effectiveness? | Annex on documentation of process; evidence table | |
14 | Is the strength of the recommendation linked to the evidence? | Summary of Recommendations | |
15 | Do the recommendations take into account potential resource constraints? | Implementation issues | |
Review | |||
16 | Were the comments by the external peer review adequately addressed? | Annex on documentation of process | |
17 | Did all members of the Guideline Development Group approve the final document? | Annex on documentation of process | |
18 | Did all members of the Steering Group approve the final document? | Annex on documentation of process | |
19 | Is there a plan for reviewing new evidence and updating the guideline? | Introduction | |
Presentation, clarity | |||
20 | Are the recommendations clearly formulated? | Summary of Recommendations | |
21 | Does the guideline identify and advise on ineffective practices? | Summary of Recommendations | |
Implementation plan | |||
22 | Is there a plan for dissemination and local adaptation of the guideline? | Companion document | |
23 | Are funds available for dissemination and local adaptation for the guideline? | Companion document | |
24 | Are there suggested criteria for monitoring the use in intended settings? | Implementation Issues |